Research progress of FLT3 inhibitors and drug resistance mechanisms in acute myeloid leukemia
10.12092/j.issn.1009-2501.2024.01.010
- Author:
Tingkai WU
1
;
Chongchong REN
1
;
Wanwan ZHANG
1
;
Bei LIU
2
Author Information
1. First Clinical Medical School, Lanzhou University
2. Department of Hematology, First Hosptial of Lanzhou University
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
drug resistance;
FLT3 inhibitors
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2024;29(1):90-98
- CountryChina
- Language:Chinese
-
Abstract:
The FMS-like tyrosine kinase 3 (FLT3) gene mutation is the most common genetic mutation in acute myeloid leukemia (AML) and is associated with poor prognosis. Various targeted inhibitors have been developed for FLT3 mutations and have shown promising clinical efficacy. However, the emergence of resistance poses new challenges for targeted therapy in AML. This article provides an overview of the pathological and prognostic role of FLT3 mutations in AML, the current research progress on commonly used FLT3 inhibitors (type I and type II), the mechanisms of FLT3 inhibitor resistance, and strategies for overcoming resistance.
